Crispr Therapeutics (NASDAQ:CRSP) Upgraded at Oppenheimer

Oppenheimer upgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a market perform rating to an outperform rating in a research report sent to investors on Tuesday, Briefing.com Automated Import reports. The brokerage currently has $65.00 price target on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ Q1 2020 earnings at ($0.87) EPS, Q2 2020 earnings at ($0.95) EPS, Q3 2020 earnings at ($1.29) EPS, Q4 2020 earnings at ($1.38) EPS, FY2021 earnings at ($4.29) EPS, FY2022 earnings at ($4.70) EPS and FY2023 earnings at ($1.07) EPS.

A number of other research analysts have also recently commented on CRSP. Zacks Investment Research cut Crispr Therapeutics from a hold rating to a sell rating in a research note on Monday, September 30th. TheStreet upgraded Crispr Therapeutics from a d rating to a c rating in a report on Monday, October 28th. BTIG Research increased their price objective on Crispr Therapeutics from $51.00 to $59.00 and gave the company a positive rating in a report on Tuesday, July 30th. BidaskClub upgraded Crispr Therapeutics from a sell rating to a hold rating in a report on Thursday, October 31st. Finally, Needham & Company LLC restated a buy rating and issued a $62.00 price objective on shares of Crispr Therapeutics in a report on Wednesday, July 31st. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $57.95.

Shares of Crispr Therapeutics stock traded up $1.81 on Tuesday, hitting $56.87. The stock had a trading volume of 763,200 shares, compared to its average volume of 749,333. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $57.40. The stock has a market cap of $3.04 billion, a price-to-earnings ratio of -16.53 and a beta of 3.15. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $43.31 and its two-hundred day moving average is $44.57.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The company had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. As a group, equities analysts predict that Crispr Therapeutics will post 0.64 earnings per share for the current fiscal year.

In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares in the company, valued at $412,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 21.40% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Benjamin Edwards Inc. grew its holdings in Crispr Therapeutics by 96.4% during the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after acquiring an additional 268 shares during the period. NEXT Financial Group Inc grew its holdings in Crispr Therapeutics by 915.0% during the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares during the period. US Bancorp DE grew its holdings in Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after acquiring an additional 526 shares during the period. Coastal Investment Advisors Inc. acquired a new stake in Crispr Therapeutics during the 3rd quarter worth about $26,000. Finally, BSW Wealth Partners acquired a new stake in Crispr Therapeutics during the 2nd quarter worth about $39,000. Hedge funds and other institutional investors own 51.09% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: If I purchase shares through a brokerage account, am I the holder of record?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.